PT100525A - Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem - Google Patents

Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem

Info

Publication number: PT100525A
Authority: PT; Portugal
Prior art keywords: immunomodular; contain; pharmaceutical compositions; treatment; azaspiranes
Prior art date: 1991-05-29

Application number

PT100525A

Other languages

English (en)

Other versions

PT100525B (pt

Inventor

David S Garvey

Youe-Kong Shue

Stephen P Arneric

Nan-Horng Lin

George M Carrera Jr

Yun He

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-29

Filing date

1992-05-28

Publication date

1993-09-30

1992-05-28 Application filed by Abbott Lab filed Critical Abbott Lab

1993-09-30 Publication of PT100525A publication Critical patent/PT100525A/pt

1999-10-29 Publication of PT100525B publication Critical patent/PT100525B/pt

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
OLROCKKMZHTZFM-UHFFFAOYSA-N 1,2-oxazole;1,2-thiazole Chemical compound C=1C=NOC=1.C=1C=NSC=1 OLROCKKMZHTZFM-UHFFFAOYSA-N 0.000 abstract 1
206010001605 Alcohol poisoning Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
208000003554 absence epilepsy Diseases 0.000 abstract 1
230000001713 cholinergic effect Effects 0.000 abstract 1
230000006949 cholinergic function Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
230000001149 cognitive effect Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
150000003217 pyrazoles Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT100525A 1991-05-29 1992-05-28 Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem PT100525B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US70692091A	1991-05-29	1991-05-29

Publications (2)

Publication Number	Publication Date
PT100525A true PT100525A (pt)	1993-09-30
PT100525B PT100525B (pt)	1999-10-29

Family

ID=24839628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT100525A PT100525B (pt)	1991-05-29	1992-05-28	Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem

Country Status (13)

Country	Link
US (1)	US5409946A (pt)
EP (1)	EP0588917B1 (pt)
JP (1)	JP3153551B2 (pt)
AT (1)	ATE197454T1 (pt)
BR (1)	BR1100981A (pt)
CA (1)	CA2109585C (pt)
DE (1)	DE69231557T2 (pt)
DK (1)	DK0588917T3 (pt)
ES (1)	ES2153360T3 (pt)
GR (1)	GR3035285T3 (pt)
IE (1)	IE921690A1 (pt)
PT (1)	PT100525B (pt)
WO (1)	WO1992021339A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69325662T2 (de) *	1992-10-23	2000-02-10	Merck Sharp & Dohme Ltd., Hoddesdon	Dopamin rezeptor subtyp liganden
US5424444A (en) *	1992-11-25	1995-06-13	Abbott Laboratories	Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles
US5494680A (en) *	1993-12-08	1996-02-27	Minnesota Mining And Manufacturing Company	Transdermal delivery device
US5723477A (en) *	1994-11-10	1998-03-03	Sibia Neurosciences, Inc.	Modulators of acetylcholine receptors
US5705512A (en) *	1994-11-10	1998-01-06	Sibia Neurosciences, Inc.	Modulators of acetylcholine receptors
US5703100A (en) *	1994-11-10	1997-12-30	Sibia Neurosciences, Inc.	Modulators of acetylcholine receptors
US5594011A (en) *	1994-11-10	1997-01-14	Sibia Neurosciences, Inc.	Modulators of acetylcholine receptors
US5677459A (en) *	1994-11-10	1997-10-14	Sibia Neurosciences, Inc.	Methods for the preparation of modulators of acetylcholine receptors
US5824692A (en) *	1995-01-06	1998-10-20	Lippiello; Patrick Michael	Pharmaceutical compositions for prevention and treatment of central nervous system disorders
DE19501022C1 (de) *	1995-01-14	1996-06-05	Lohmann Therapie Syst Lts	Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung
AU5014396A (en) *	1995-03-24	1996-10-16	Japan Tobacco Inc.	Diazabicyclo{3.3.1}nonane derivatives and intermediates ther eof, medicinal use of the same, and processes for producing the same
US6194581B1 (en)	1995-04-07	2001-02-27	Merck & Co., Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) *	1995-05-17	1996-12-10	Bencherif; Merouane	Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en)	1995-11-17	1998-08-18	Komerath; Narayanan M.	Stagnation point vortex controller
US5723414A (en) *	1996-01-24	1998-03-03	Rohm And Haas Company	5-aryl-isoxazolinones and herbicidal use thereof
JP4357001B2 (ja)	1996-04-23	2009-11-04	ターガセプト，インコーポレイテッド	中枢神経系障害の予防及び治療のための医薬組成物
US5706829A (en) *	1996-06-06	1998-01-13	Creighton University	Method for treating neurocardiogenic syncope
US5760049A (en) *	1997-02-21	1998-06-02	Synapse Pharmaceuticals International, Inc.	Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6166032A (en) *	1997-02-07	2000-12-26	Synapse Pharmaceuticals International, Inc.	Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
KR100589872B1 (ko)	1997-05-30	2006-06-15	뉴로서치 에이/에스	8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
JP2002511068A (ja)	1997-05-30	2002-04-09	ニューロサーアチ・アクティーゼルスカブ	アザシクロオクタン及びヘプタン誘導体、その製造方法及びこれを用いて治療する方法
WO1998054182A1 (en) *	1997-05-30	1998-12-03	Neurosearch A/S	9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
US6133002A (en)	1997-09-25	2000-10-17	Dsm N.V.	Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6218383B1 (en)	1998-08-07	2001-04-17	Targacept, Inc.	Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2001068104A1 (en) *	2000-03-16	2001-09-20	The Mclean Hospital Corporation	Compounds for the treatment of psychiatric or substance abuse disorders
BR0316054A (pt) *	2002-11-08	2005-09-20	Mclean Hospital Corp	Compostos para tratamento de dependência e privação de tabaco
JP4717444B2 (ja) *	2002-12-20	2011-07-06	ザマクレーンホスピタルコーポレーション	睡眠／覚醒サイクルの正規化のための化合物
US20050113449A1 (en) *	2003-10-08	2005-05-26	Renshaw Perry F.	Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20050129710A1 (en) *	2003-10-08	2005-06-16	Renshaw Perry F.	Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005037832A2 (en)	2003-10-15	2005-04-28	Targacept, Inc.	Azabicycyclic compounds for relieving pain and treating central nervous system disorders
FR2862647B1 (fr) *	2003-11-25	2008-07-04	Aventis Pharma Sa	Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US20090215714A1 (en) *	2004-06-10	2009-08-27	Perry Renshaw	Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
EP1765075A4 (en) *	2004-06-10	2010-11-10	Mclean Hospital Corp	PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
US7947661B2 (en) *	2004-08-11	2011-05-24	The Mclean Hospital Corporation	Compounds for the treatment of marihuana dependence, withdrawal, and usage
AU2005284908B2 (en)	2004-09-13	2011-12-08	Morningside Venture Investments Limited	Biosynchronous transdermal drug delivery
CN103977003A (zh)	2007-04-02	2014-08-13	帕金森氏病研究院	用于降低治疗的副作用的方法和组合物
US20100041621A1 (en) *	2008-08-15	2010-02-18	Perry Renshaw	Methods and compositions for improving cognitive performance
CA2736871C (en) *	2008-09-11	2019-03-12	Catholic Healthcare West	Nicotinic attenuation of cns inflammation and autoimmunity
JP2013516497A (ja)	2010-01-11	2013-05-13	ミスリィディオン，インク．	認知増強のための化合物と組成物、製造方法、および治療方法
WO2012033956A1 (en)	2010-09-08	2012-03-15	Mithridion, Inc.	Cognition enhancing compounds and compositions, methods of making, and methods of treating
JP6114841B2 (ja)	2013-02-28	2017-04-12	ダーミラ，インク．Ｄｅｒｍｉｒａ，Ｉｎｃ．	グリコピロレート塩
US9006462B2 (en)	2013-02-28	2015-04-14	Dermira, Inc.	Glycopyrrolate salts
AU2016211330A1 (en)	2015-01-28	2017-08-03	Chrono Therapeutics Inc.	Drug delivery methods and systems
CA3049529A1 (en)	2017-01-06	2018-07-12	Chrono Therapeutics Inc.	Transdermal drug delivery devices and methods
US11596779B2 (en)	2018-05-29	2023-03-07	Morningside Venture Investments Limited	Drug delivery methods and systems
US12397141B2 (en)	2018-11-16	2025-08-26	Morningside Venture Investments Limited	Thermally regulated transdermal drug delivery system

1992
- 1992-05-28 ES ES92912971T patent/ES2153360T3/es not_active Expired - Lifetime
- 1992-05-28 EP EP92912971A patent/EP0588917B1/en not_active Expired - Lifetime
- 1992-05-28 WO PCT/US1992/004631 patent/WO1992021339A1/en not_active Ceased
- 1992-05-28 DK DK92912971T patent/DK0588917T3/da active
- 1992-05-28 DE DE69231557T patent/DE69231557T2/de not_active Expired - Lifetime
- 1992-05-28 AT AT92912971T patent/ATE197454T1/de not_active IP Right Cessation
- 1992-05-28 PT PT100525A patent/PT100525B/pt active IP Right Grant
- 1992-05-28 JP JP50062493A patent/JP3153551B2/ja not_active Expired - Fee Related
- 1992-05-28 CA CA002109585A patent/CA2109585C/en not_active Expired - Lifetime
- 1992-07-01 IE IE169092A patent/IE921690A1/en not_active IP Right Cessation
1993
- 1993-09-08 US US08/118,079 patent/US5409946A/en not_active Expired - Lifetime
1997
- 1997-05-14 BR BR1100981-0A patent/BR1100981A/pt active IP Right Grant
2001
- 2001-01-24 GR GR20010400099T patent/GR3035285T3/el unknown

Also Published As

Publication number	Publication date
DE69231557D1 (de)	2000-12-14
PT100525B (pt)	1999-10-29
JP3153551B2 (ja)	2001-04-09
DE69231557T2 (de)	2001-06-21
IE921690A1 (en)	1992-12-02
US5409946A (en)	1995-04-25
EP0588917B1 (en)	2000-11-08
ATE197454T1 (de)	2000-11-11
CA2109585C (en)	2000-02-15
CA2109585A1 (en)	1992-12-10
EP0588917A1 (en)	1994-03-30
JPH06508143A (ja)	1994-09-14
BR1100981A (pt)	2000-04-18
EP0588917A4 (pt)	1994-04-13
WO1992021339A1 (en)	1992-12-10
GR3035285T3 (en)	2001-04-30
DK0588917T3 (da)	2001-02-12
ES2153360T3 (es)	2001-03-01

Legal Events

Date	Code	Title	Description
1993-09-30	BB1A	Laying open of patent application	Effective date: 19930427
1999-10-29	FG3A	Patent granted, date of granting	Effective date: 19990707

Publication	Publication Date	Title
PT100525A (pt)	1993-09-30	Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem
KR950702829A (ko)	1995-08-23	신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체
PT100631A (pt)	1993-09-30	Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem
DE69426331D1 (de)	2000-12-28	Arzneimittel gegen nervöse erkrankungen
ATE170530T1 (de)	1998-09-15	Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
FI944823A0 (fi)	1994-10-13	Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
ES2098023T3 (es)	1997-04-16	Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ATE73785T1 (de)	1992-04-15	5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amin - 6h-1,3,4-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
DE69625709D1 (de)	2003-02-13	Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten
ATE23160T1 (de)	1986-11-15	Neue pyridobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
SE8503109L (sv)	1985-12-22	Cykliska forstadielekemedel till antiinflammatoriska oxikamer
KR910000143A (ko)	1991-01-29	간질치료제로서의 5-페닐-2- 푸란 에스테르 및 아미드의 용도
AU1621392A (en)	1992-11-19	New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them
DE59104473D1 (de)	1995-03-16	Arzneimittel welche substituierte 2-Cyclohexen-1yl-amin-Derivate enthalten und ihre Verwendung zur Bekämpfung von Krankheiten.
AU579416B2 (en)	1988-11-24	3-Amino-2,3-dihydro-1-benzoxepine-compounds and methods for their preparation and pharmaceutical preparations containing these compounds
ATE83484T1 (de)	1993-01-15	20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
TH18473A (th)	1996-05-09	การใช้เวนลาแฟกซีนหรือสารประกอบแอริลออกซิ โพรแพแนมีนในการผลิตยาสำหรับการรักษาการกลั้นปัสสาวะไม่อยู่
TH20919A (th)	1996-10-08	สารประกอบชนิดเฮเทอโรไซคลิคและการเตรียมและการใช้สารประกอบเหล่านี้